All In MedTech

FDA Clearance Tracker · P140031-S087

SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valves

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 29, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 29, 2019

Approved

Time to decision

73 days

Received May 17, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P140031-S087
Device name
SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valves
Applicant location
Irvine, CA
Received
May 17, 2019
Decided
Jul 29, 2019
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P140031

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for updates to the labeling of the SAPIEN 3 Transcatheter Heart Valve and Accessories and SAPIEN 3 Ultra Transcatheter Heart Valve and Accessories regarding additional valve-in-valve sizing guidance for implantation inside the Edwards INSPIRIS RESILIA aortic valve model 11500A.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.